WuXi AppTec and New World Development-backed Adagene has raised close to $140m in its initial public offering after having secured $155m in equity financing.
Adagene, a China-based immuno-oncology drug developer backed by pharmaceutical firm WuXi AppTec and conglomerate New World Development, has raised nearly $140m in its initial public offering. The company issued approximately 7.35 million American Depositary Shares (ADSs), representing just over 9.19 million ordinary shares, priced at $19 each. It now trades on the Nasdaq Global Market…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
